Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF Mutant Melanoma”

68 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 68 results

Testing effectiveness (Phase 2)Ended earlyNCT01616199
What this trial is testing

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Who this might be right for
Advanced BRAF-mutant Cancers
Cascadian Therapeutics Inc. 24
Testing effectiveness (Phase 2)Ended earlyNCT01777776
What this trial is testing

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Who this might be right for
Locally Advanced Metastatic BRAF Mutant Melanoma
Array BioPharma 28
Early research (Phase 1)WithdrawnNCT02915666
What this trial is testing

A Clinical Trial of Patients With Melanoma

Who this might be right for
Melanoma
University of Texas Southwestern Medical Center
Large-scale testing (Phase 3)WithdrawnNCT02427893
What this trial is testing

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Who this might be right for
Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Early research (Phase 1)Ended earlyNCT01940809
What this trial is testing

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Melanoma+5 more
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)WithdrawnNCT03005639
What this trial is testing

ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma

Who this might be right for
Stage IIIB-C Melanoma
Inova Health Care Services
Large-scale testing (Phase 3)Study completedNCT01667419
What this trial is testing

Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma

Who this might be right for
Melanoma
Hoffmann-La Roche 498
Large-scale testing (Phase 3)Study completedNCT01909453
What this trial is testing

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

Who this might be right for
Melanoma
Pfizer 921
Early research (Phase 1)Study completedNCT01436656
What this trial is testing

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Who this might be right for
Melanoma and Metastatic Colorectal Cancer
Pfizer 107
Testing effectiveness (Phase 2)Study completedNCT02296996
What this trial is testing

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

Who this might be right for
Malignant Melanoma
Universitair Ziekenhuis Brussel 25
Early research (Phase 1)Ended earlyNCT04543188
What this trial is testing

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Who this might be right for
Malignant MelanomaCarcinoma, Non-Small-Cell LungBrain Neoplasms, Primary+2 more
Pfizer 65
Testing effectiveness (Phase 2)Ended earlyNCT01495988
What this trial is testing

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Who this might be right for
MelanomaMetastatic Melanoma
Melanoma Research Foundation Breakthrough Consortium 10
Early research (Phase 1)Ended earlyNCT03272464
What this trial is testing

INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

Who this might be right for
Melanoma
Massachusetts General Hospital 1
Testing effectiveness (Phase 2)Study completedNCT01153763
What this trial is testing

GSK2118436 in BRAF Mutant Metastatic Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline 92
Testing effectiveness (Phase 2)Active Not RecruitingNCT01989585
What this trial is testing

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Malignant Solid Neoplasm+2 more
National Cancer Institute (NCI) 75
Early research (Phase 1)Study completedNCT03415126
What this trial is testing

ASN007 in Patients With Advanced Solid Tumors

Who this might be right for
CancerMalignancyNeoplasia+16 more
Asana BioSciences 49
Early research (Phase 1)Study completedNCT05668585
What this trial is testing

Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

Who this might be right for
Solid TumorsMelanomaNSCLC+2 more
C4 Therapeutics, Inc. 89
Large-scale testing (Phase 3)Study completedNCT01227889
What this trial is testing

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Who this might be right for
Cancer
GlaxoSmithKline 251
Testing effectiveness (Phase 2)UnknownNCT02858921
What this trial is testing

Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

Who this might be right for
Melanoma
Melanoma Institute Australia 60
Early research (Phase 1)Ended earlyNCT03878719
What this trial is testing

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Who this might be right for
Melanoma
Pfizer 1
Load More Results